NCT05340725 (DEX-NANO) is a Phase 2, PHASE3 clinical trial of DEX-IV in Postoperative Pain, sponsored by Assiut University.

Who is sponsoring NCT05340725?

NCT05340725 is sponsored by Assiut University.

What drugs are being tested in NCT05340725?

Interventions in NCT05340725: DEX-IV, DEX-Rectal, DEX-Nano-Rectal.

What condition does NCT05340725 study?

NCT05340725 studies Postoperative Pain.

Is NCT05340725 still recruiting?

NCT05340725 is currently status unknown. Last updated 23 January 2023.

Last reviewed 2023-01-23 · How we verify

NCT05340725: DEX-NANO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rectal Dexmedetomidine Niosomes for Postoperative Analgesia in Pediatric Cancer Patients.

Status unknown Phase 2, PHASE3 Last updated 23 January 2023

What this trial tests

Phase 2, PHASE3 trial testing DEX-IV in Postoperative Pain in 45 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
1 December 2023

1 December 2023

Quick facts

Lead sponsor	Assiut University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	45
Start date	1 May 2022
Primary completion	1 December 2023
Estimated completion	1 December 2023
Sites	1 location across Egypt

Drugs / interventions tested

DEX-IV — full drug profile →
DEX-Rectal — full drug profile →
DEX-Nano-Rectal — full drug profile →

Conditions studied

Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

Assiut University

Who can join

Adults 3 to 7, any sex, with Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Applying nanotechnology in drug delivery systems improved the bioavailability and kinetic profile of drugs in biological systems

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Advances of medical nanorobots for future cancer treatments.
Kong X, Gao P, Wang J, Fang Y, et al · · 2023 · cited 74× · PMID 37452423 · DOI 10.1186/s13045-023-01463-z
Nanotechnology-based delivery systems to overcome drug resistance in cancer.
Patel H, Patel H, Li J, Bo L, et al · · 2024 · cited 9× · PMID 38515777 · DOI 10.1515/mr-2023-0058
Niosomes as Vesicular Carriers: From Formulation Strategies to Stimuli-Responsive Innovative Modulations for Targeted Drug Delivery.
Ababei-Bobu A, Profire BȘ, Iacob AT, Chirliu OM, et al · · 2025 · cited 3× · PMID 41304810 · DOI 10.3390/pharmaceutics17111473
Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.
Wusiman D, Wang Y, Wang M, Wang J, et al · · 2025 · cited 3× · PMID 40791791 · DOI 10.1016/j.mtbio.2025.102116
Nanomedicine Therapies for Pediatric Diseases.
Yang S, Aggarwal K, Jurczyszak J, Brown N, et al · · 2024 · cited 2× · PMID 39420230 · DOI 10.1002/wnan.1996

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05340725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 23 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05340725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing